These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8070158)

  • 1. Treatment of systemic lupus erythematosus with lobenzarit: an open clinical trial.
    Hirohata S; Ohnishi K; Sagawa A
    Clin Exp Rheumatol; 1994; 12(3):261-5. PubMed ID: 8070158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of in vitro anti-DNA antibody production by a novel disease modifying anti-rheumatic drug, Lobenzarit.
    Hirohata S
    Clin Exp Rheumatol; 1992; 10(4):357-63. PubMed ID: 1356678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary study of a traditional Chinese medicine formula in systemic lupus erythematosus patients to taper steroid dose and prevent disease flare-up.
    Liao YN; Liu CS; Tsai TR; Hung YC; Chang SJ; Lin HL; Chen YC; Lai HM; Yu SF; Chen CJ
    Kaohsiung J Med Sci; 2011 Jul; 27(7):251-7. PubMed ID: 21757141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of methotrexate on improving serological abnormalities of patients with systemic lupus erythematosus.
    Miyawaki S; Nishiyama S; Aita T; Yoshinaga Y
    Mod Rheumatol; 2013 Jul; 23(4):659-66. PubMed ID: 23011357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of protein-losing gastroenteropathy in systemic lupus erythematosus treated with prednisolone and azathioprine.
    Mok CC; Ying KY; Mak A; To CH; Szeto ML
    Rheumatology (Oxford); 2006 Apr; 45(4):425-9. PubMed ID: 16234272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease).
    Gansauge S; Breitbart A; Rinaldi N; Schwarz-Eywill M
    Ann Rheum Dis; 1997 Jun; 56(6):382-5. PubMed ID: 9227169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus.
    Toubi E; Kessel A; Rosner I; Rozenbaum M; Paran D; Shoenfeld Y
    Scand J Immunol; 2006 Apr; 63(4):299-303. PubMed ID: 16623930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
    Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J
    Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open study of B lymphocyte depletion in systemic lupus erythematosus.
    Leandro MJ; Edwards JC; Cambridge G; Ehrenstein MR; Isenberg DA
    Arthritis Rheum; 2002 Oct; 46(10):2673-7. PubMed ID: 12384926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open label randomized controlled trial assessing the efficacy of mycophenolate sodium against other conventional immunosuppressive agents in active systemic lupus erythematosus patients without renal involvement.
    Yahya F; Jasmin R; Ng CT; Cheah TE; Sockalingam S
    Int J Rheum Dis; 2013 Dec; 16(6):724-30. PubMed ID: 24119227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of mizoribine in the treatment of systemic lupus erythematosus in children.
    Yoshidome K; Takei S; Imanaka H; Maeno N; Ohkawa T; Kawano Y
    Pediatr Int; 2004 Aug; 46(4):444-9. PubMed ID: 15310311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 2 year, open ended trial of methotrexate in systemic lupus erythematosus.
    Wilson K; Abeles M
    J Rheumatol; 1994 Sep; 21(9):1674-7. PubMed ID: 7799348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus.
    Tanaka Y; Yamamoto K; Takeuchi T; Nishimoto N; Miyasaka N; Sumida T; Shima Y; Takada K; Matsumoto I; Saito K; Koike T
    Mod Rheumatol; 2007; 17(3):191-7. PubMed ID: 17564773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Very early development of steroid-associated osteonecrosis of femoral head in systemic lupus erythematosus: prospective study by MRI.
    Nagasawa K; Tada Y; Koarada S; Horiuchi T; Tsukamoto H; Murai K; Ueda A; Yoshizawa S; Ohta A
    Lupus; 2005; 14(5):385-90. PubMed ID: 15934439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
    Szepietowski JC; Nilganuwong S; Wozniacka A; Kuhn A; Nyberg F; van Vollenhoven RF; Bengtsson AA; Reich A; de Vries DE; van Hartingsveldt B; Robinson DW; Gordon R; Hsu B
    Arthritis Rheum; 2013 Oct; 65(10):2661-71. PubMed ID: 23896980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.
    Leandro MJ; Cambridge G; Edwards JC; Ehrenstein MR; Isenberg DA
    Rheumatology (Oxford); 2005 Dec; 44(12):1542-5. PubMed ID: 16188950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urticarial vasculitis in systemic lupus erythematosus: fair response to prednisolone/dapsone and persistent hypocomplementemia.
    Nishijima C; Hatta N; Inaoki M; Sakai H; Takehara K
    Eur J Dermatol; 1999; 9(1):54-6. PubMed ID: 9920991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.
    Furie RA; Leon G; Thomas M; Petri MA; Chu AD; Hislop C; Martin RS; Scheinberg MA;
    Ann Rheum Dis; 2015 Sep; 74(9):1667-75. PubMed ID: 24748629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial.
    Abdou NI; Rider V; Greenwell C; Li X; Kimler BF
    J Rheumatol; 2008 May; 35(5):797. PubMed ID: 18381791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.